ACLX
Price:
$71.25
Market Cap:
$3.83B
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known...[Read more]
Industry
Biotechnology
IPO Date
2022-02-04
Stock Exchange
NASDAQ
Ticker
ACLX
According to Arcellx, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.01. This represents a change of 17.99% compared to the average of 5.09 of the last 4 quarters.
The mean historical Current Ratio of Arcellx, Inc. over the last ten years is 8.05. The current 6.01 Current Ratio has changed 7.36% with respect to the historical average. Over the past ten years (40 quarters), ACLX's Current Ratio was at its highest in in the March 2022 quarter at 13.14. The Current Ratio was at its lowest in in the March 2021 quarter at 0.
Average
8.05
Median
7.83
Minimum
4.71
Maximum
12.53
Discovering the peaks and valleys of Arcellx, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 55.50%
Maximum Annual Current Ratio = 12.53
Minimum Annual Increase = -38.06%
Minimum Annual Current Ratio = 4.71
Year | Current Ratio | Change |
---|---|---|
2023 | 6.06 | 28.71% |
2022 | 4.71 | -38.06% |
2021 | 7.60 | -18.85% |
2020 | 9.36 | -25.25% |
2019 | 12.53 | 55.50% |
The current Current Ratio of Arcellx, Inc. (ACLX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
6.12
5-year avg
8.05
10-year avg
8.05
Arcellx, Inc.’s Current Ratio is less than Nuvalent, Inc. (17.44), less than Ventyx Biosciences, Inc. (14.19), greater than Amylyx Pharmaceuticals, Inc. (4.66), greater than Day One Biopharmaceuticals, Inc. (4.09), greater than Biomea Fusion, Inc. (4.62),
Company | Current Ratio | Market cap |
---|---|---|
17.44 | $5.59B | |
14.19 | $153.35M | |
4.66 | $161.36M | |
4.09 | $1.25B | |
4.62 | $256.37M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcellx, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arcellx, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Arcellx, Inc.'s Current Ratio?
How is the Current Ratio calculated for Arcellx, Inc. (ACLX)?
What is the highest Current Ratio for Arcellx, Inc. (ACLX)?
What is the 3-year average Current Ratio for Arcellx, Inc. (ACLX)?
What is the 5-year average Current Ratio for Arcellx, Inc. (ACLX)?
How does the current Current Ratio for Arcellx, Inc. (ACLX) compare to its historical average?